Comerica Bank grew its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 0.4% during the 3rd quarter, Holdings Channel.com reports. The firm owned 109,680 shares of the company’s stock after acquiring an additional 463 shares during the period. Comerica Bank’s holdings in Myriad Genetics were worth $3,585,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of MYGN. Nuveen Asset Management LLC boosted its position in shares of Myriad Genetics by 4,582.1% during the 2nd quarter. Nuveen Asset Management LLC now owns 673,941 shares of the company’s stock worth $18,722,000 after purchasing an additional 659,547 shares in the last quarter. BlackRock Inc. boosted its position in shares of Myriad Genetics by 4.2% during the 2nd quarter. BlackRock Inc. now owns 12,535,346 shares of the company’s stock worth $348,233,000 after purchasing an additional 509,214 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Myriad Genetics by 57.7% during the 2nd quarter. Point72 Asset Management L.P. now owns 982,601 shares of the company’s stock worth $27,297,000 after purchasing an additional 359,488 shares in the last quarter. Morgan Stanley boosted its position in shares of Myriad Genetics by 298.7% during the 2nd quarter. Morgan Stanley now owns 472,822 shares of the company’s stock worth $13,136,000 after purchasing an additional 354,233 shares in the last quarter. Finally, Invesco Ltd. boosted its position in shares of Myriad Genetics by 19.7% during the 2nd quarter. Invesco Ltd. now owns 1,856,133 shares of the company’s stock worth $51,563,000 after purchasing an additional 305,143 shares in the last quarter.

Several research firms recently commented on MYGN. Needham & Company LLC reiterated a “hold” rating on shares of Myriad Genetics in a research report on Tuesday, November 5th. Deutsche Bank decreased their price objective on shares of Myriad Genetics from $45.00 to $35.00 and set a “hold” rating on the stock in a research report on Wednesday, August 14th. Barclays decreased their price objective on shares of Myriad Genetics from $22.00 to $18.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 5th. BidaskClub upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Thursday, October 24th. Finally, Piper Jaffray Companies decreased their price objective on shares of Myriad Genetics from $40.00 to $22.00 in a research report on Tuesday, November 5th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $28.04.

In other news, Director John T. Henderson bought 5,250 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was acquired at an average price of $23.46 per share, for a total transaction of $123,165.00. Following the acquisition, the director now owns 64,353 shares of the company’s stock, valued at $1,509,721.38. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 5.90% of the stock is currently owned by insiders.

Myriad Genetics stock opened at $23.64 on Friday. The company has a quick ratio of 2.69, a current ratio of 2.86 and a debt-to-equity ratio of 0.27. Myriad Genetics, Inc. has a 52 week low of $20.10 and a 52 week high of $48.40. The firm has a market capitalization of $1.56 billion, a PE ratio of 18.33, a P/E/G ratio of 1.61 and a beta of 0.96. The firm’s 50-day simple moving average is $29.72 and its 200 day simple moving average is $28.51.

Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.26 by ($0.18). Myriad Genetics had a positive return on equity of 6.48% and a negative net margin of 1.83%. The firm had revenue of $186.30 million for the quarter, compared to analysts’ expectations of $202.34 million. During the same quarter in the previous year, the firm posted $0.43 EPS. The firm’s revenue for the quarter was down 7.9% compared to the same quarter last year. On average, research analysts expect that Myriad Genetics, Inc. will post 0.75 EPS for the current fiscal year.

Myriad Genetics Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.